Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Practical Considerations Cost differences between tirzepatide and semaglutide can influence treatment selection
Long-term nasal spray use carries theoretical concerns about mucosal damage
If you feel particularly foggy, consider checking your glucose levels
1 The study details 800 participants in the interim analysis (1,197 total enrolled) with biopsy-confirmed MASH and moderate to severe fibrosis (stage F2 or F3) Participants were randomly assigned to receive semaglutide 2.4 mg weekly or placebo Treatment lasted 72 weeks 2:1 randomisation (534 semaglutide, 266 placebo) Resolution of MASH (primary outcome) Fibrosis improvement (primary outcome) Combined outcomes About a third (32.7%) of participants taking semaglutide achieved both MASH resolution and fibrosis improvement, compared to 16.1% on placebo
